EP0684815A1 - Drug delivery system using hollow fibers - Google Patents

Drug delivery system using hollow fibers

Info

Publication number
EP0684815A1
EP0684815A1 EP94909798A EP94909798A EP0684815A1 EP 0684815 A1 EP0684815 A1 EP 0684815A1 EP 94909798 A EP94909798 A EP 94909798A EP 94909798 A EP94909798 A EP 94909798A EP 0684815 A1 EP0684815 A1 EP 0684815A1
Authority
EP
European Patent Office
Prior art keywords
fibers
fiber
voids
substance
hollow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94909798A
Other languages
German (de)
French (fr)
Other versions
EP0684815A4 (en
Inventor
Sam S. Ahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0684815A1 publication Critical patent/EP0684815A1/en
Publication of EP0684815A4 publication Critical patent/EP0684815A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/44Medicaments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/46Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • DTEXTILES; PAPER
    • D06TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06MTREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M16/00Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
    • DTEXTILES; PAPER
    • D06TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06MTREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M16/00Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
    • D06M16/003Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic with enzymes or microorganisms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2913Rod, strand, filament or fiber
    • Y10T428/2933Coated or with bond, impregnation or core
    • Y10T428/2971Impregnation

Definitions

  • the hollow space are delivered to the immediate environment of the fiber through the two ends of the fibers to which the interior hollow reaches.
  • the present invention also includes a method of using a vacuum chamber for filling the hollow fibers with the contents to be delivered. This comprises taking the original hollow fibers, with only air trapped in the hollow spaces within the fibers, and submerging the fibers in a container containing a solution of the drugs or other chemicals that are targeted to be contained in the fibers. The container with the solution of fibers is then placed in a vacuum chamber and the air pressure is reduced in the vacuum chamber. This draws out the air within the hollow within the fiber, creating a vacuum in the fiber voids. With the fibers still submerged in the solution, the air pressure is then restored inside the vacuum chamber. This causes the vacuum within the fibers to draw the liquid solution into the hollows of the fibers, replacing the vacuum with the liquid solution.
  • Fibers filled with liquid look clear without dark streaks because the refractive indexes of the fiber and the liquid are similar. However, unremoved air remaining in the hollows in the fibers appears as dark streaks because of significantly different refractive indexes of the fiber and the air.
  • Figure 1 shows a cross section of a typical single-hole hollow fiber.
  • Figure 2 shows a schematic side view of a typical single-hole hollow fiber.
  • Figure 3 shows a schematic view of the apparatus for filling the hollow fibers with a substance.
  • Figure 4 shows a schematic side view of a hollow fiber submerged in a liquid but still full of air.
  • Figure 5 shows a hollow fiber submerged in a liquid when the atmospheric pressure is being reduced, drawing the air out of the hollow.
  • Figure 6 shows a schematic side view of a hollow fiber after the hollow fiber void is filled with liquid.
  • Figure 7 shows a cross section of a typical four-hole hollow fiber.
  • Figure 8 shows a cross section of a typical seven-hole fiber.
  • Figure 1 shows a cross section view of a typical single-hole hollow fiber with the fiber material 1 and the hollow space 2.
  • Figure 2 shows a side schematic view of a typical hollow fiber showing the fiber material 1, the hollow space 2 inside the fiber, and the end of the hollow which allows air and liquid to enter and exit through the end of the fiber 3.
  • Figure 3 shows a schematic view of the apparatus using a vacuum chamber to fill the substance into the fiber.
  • a mass of fibers 4 is shown as hash marks. These are placed in a container 5 which holds a liquid substance 6.
  • the container 5 with the fibers 4 and liquid substance 6 is placed within a vacuum chamber 7 which has an air exit 8 and vacuum pump 9.
  • air exit 8 and vacuum pump 9 When the vacuum pump 9 is operated, air is withdrawn from inside the vacuum chamber 7 creating the vacuum inside the chamber as well as inside the hollow fiber.
  • the control valve is loosened, air is let back into the vacuum chamber 7 allowing the air pressure there to return to normal.
  • the fibers 4 are placed in the container 5 and the solution 6 is added submerging the fibers.
  • Figure 4 shows a schematic cross sectional view of a fiber in this situation. The fiber is surrounded by a liquid solution which penetrates slightly through the ends of the fiber by capillary action.
  • FIG. 6 shows a cross sectional view of the fiber in this condition. Liquid 11 has been drawn into the fiber filling the entire hollow.
  • the rate of delivery of the contents from the fibers is controlled by controlling the length of the fibers. That is, the rate of delivery of the contents will be approximately inversely proportional to the length of the fiber. That is, longer fibers of a certain length X will have a rate of delivery that is one half of the rate of delivery of shorter fibers with a length of one half X. this is because the shorter fibers will have twice the number of end holes per unit weight of fiber or per unit weight of contents held and to be delivered.
  • the rate of delivery can also be varied by changing the total cross-sectional area of the hollows.
  • the total percentage hollow area in cross section can be altered by changing each fiber's percentage of hollowness. A higher rate of delivery can be obtained by increasing each fiber's percentage hollowness. Likewise, a lower rate of delivery can be obtained by reducing the fiber's percentage hollowness.
  • the rate of delivery of the contents can also be controlled by controlling the fiber size. A larger fiber will deliver the drug at a higher rate, and a smaller fiber will deliver the drug at a lower rate.
  • the rate of delivery of the contents can be controlled by controlling the concentration of the drug.
  • a higher drug concentration yields a higher diffusion rate.
  • a lower concentration yields a lower diffusion rate.
  • the rate of delivery of the contents from the fibers may also be controlled by using a dull instrument to cut the fibers.
  • a dull instrument rather than a sharp instrument will partially pinch the fiber in cutting it, thereby restricting the size of the end hole in the fiber.
  • Tests run by the inventor have shown that this method deposits drug solutions within hollow fibers.
  • the fibers released the drugs slowly at rates that have been made to vary from 3 days to 2 weeks by altering the length of the fibers, the number of hollows in each fiber, and the fiber diameter.
  • Basic hollow fibers of this type can be made of polyethylene terephthalate, rayon, nylon, TeflonTM or cotton.
  • Cotton is a natural fiber that is naturally hollow. Applications of such impregnated fibers and materials can be used for both medical and non-medica1 purposes.
  • Fibers and fabrics made in this manner that are treated with antibiotics to prevent infection and to encourage healing, can be used for certain kinds of prostheses, such as vascular grafts.
  • An artificial graft made of such material can be filled with an antibiotic to prevent post-operation infections around the surgical field, with steroids to prevent rejection of the graft material, and with antimetabolites to prevent excessive scar formation around the graft.
  • they may be filled with Heparin, an anticoagulant, to prevent excessive clotting around the prosthesis.
  • insect repellants or insecticides can be filled into materials and fabrics in this manner to make clothing that repels insects.
  • the present invention may also be used to deliver antifungal agents through diapers to prevent diaper rash.
  • Such a drug used in this manner would release from the fabric only when wet, which is of course when they are most needed in this application.
  • the active ingredient to be placed in the fibers is normally a dry powder
  • the ingredient must be dissolved in water, alcohol, or another solvent (or placed in a liquid in an emulsion, suspension, slurry or other form) , in order to be put into the hollow fiber as discussed above.
  • the fiber will usually be dried before being worked or used. This can be done by freeze-drying, convection drying, or by micro-wave or other heating. This will leave the dry active ingredient in the hollow of the dry fiber, which can then be worked to make the final product (which can be stored in dry form) .
  • the product made from the fiber can be wetted with the appropriate liquid to restore the active ingredient to its liquid form and make it readily diffusible out of the fiber.
  • the product also can be used dry where it will be adequately wetted after application (due to the wetness of the site of use) to allow diffusion of the active ingredient.
  • Active ingredients that are inherently liquids cannot be dried, and must be worked, stored and used as liquids.
  • any natural and artificial materials may be used to make the hollow fibers which are then filled with the agents for later delivery.
  • the filled fibers may be mixed and used with a variety of other fibers that are untreated or treated, to form composite materials for uses incorporating delivery of the drugs or other carried agents.
  • different medical and non-medical agents and chemicals not described herein may also be used for delivery by the hollow fibers described herein.
  • the material made from the fibers, and the fibers themselves, may be manufactured into a variety of other finished products which could then be used for other uses including the timed delivery of the agents that they contain.
  • hollow fibers can also be made of cellulose, polyacrylonitrile, acetate, rayon, polyamide (nylon) , polyethylene terephthalate (polyester), cotton, polyvinyl alcohol, polyvinyl, polyethylene, polypeptide, polypropylene, polystyrene, polyvinylchloride, or polyurethane.
  • a vacuum in the chamber was used of from 10 -2 torr. to 10 -4 torr. , but other vacuum pressures can be used.
  • Any drug may be incorporated into the hollow by the present invention, and this may include hydrophilic (aqueous based) , hydrophobic (oil or lipid based) , or slurries (liquid in combination with solid particles) .
  • the drugs or other contents may be released from the hollows within the fibers by diffusion, vaporization, capillary action, liquid flow, liquid leakage, or other means.
  • the solid drugs may leave the hollow fiber by redissolving when in contact with new liquids and moving out by diffusion, capillary action, or a liquid flow.
  • Fabrics made out of the treated materials as described herein may be knitted, woven, or non-woven fabrics.
  • Medical sheets and gowns are currently often made by non- woven polyethylene terephthalate fibers which are chopped are then pressed. They may be bonded or mechanically-entangled or otherwise formed into fabric in a method similar to manufactured paper. Articles that may be made out of materials treated in this manner may include also disposable shoe covers for the surgical theater. Furthermore, a non-woven material may be used to make products such as diapers, sheets, masks, gowns, surgical caps, shoe covers and bandages.
  • Knitted or woven fabrics may be used for the manufacture of vascular grafts, other prosthetic grafts, sutures, pillows, disposable tarps, disposable clothes or nets, or other materials.
  • Fragrances or sleep-inducing drugs may also be incorporated in the materials to be released as vapors.
  • the present invention may also be incorporated into artificial insulating fabrics such as ThinsulateTM, to make insulated disposable clothes or nets filled with chemicals.
  • These chemicals can include insect repellant to be used in sporting or outdoor environments.
  • mildew resistant chemicals or drugs could be used for such outdoor applications.
  • rain gear may be made of hollow fiber, fabrics treated in this matter to contain water-repellant materials. This may yield a fabric that is both water repellant but can "breathe", that is, it can pass air and water vapor between the weave of the fabric.
  • hollow polyethylene terephthalate fibers are hydrophobic and normally do not wet well.
  • these fibers can be made hydrophilic (i.e., easily wetable) by treating them with a basic solution.
  • a basic solution such as sodium hydroxide and ethanol, and then rinsed with distilled water, to make them hydrophilic.
  • fibers with one axial hollow For example, for convenience in explanation, embodiments are shown and described in this specification with fibers with one axial hollow. However, a fiber with multiple parallel axial hollows within each length of fiber can equally as well embody this invention. For example, fibers are currently made and can be used in the present invention that have one, four and seven hollows, respectively, running for the length of the fiber.
  • Figure 7 shows a cross section view of a four-hole hollow fiber with the fiber material 1 and the four hollow spaces 2.
  • Figure 8 shows a cross section view of a seven-hole hollow fiber with the fiber material 1 and the seven hollow spaces 2.
  • Table I describes the results of preparation of commercially available hollow DacronTM (polyethylene terephthalate made by DuPont) fiber, 1.3 denier per filament T-727W (single-hole with 15% void) , with vacuum-filling of the hollow fibers with salt solution, and testing the filled fiber for controlled time release of the salt solution.
  • a 4.0 gram sample of 3.81 centimeters cut length was prepared by cutting the fiber with a sharp razor. The fiber diameter was 11.56 microns and the void diameter was 4.49 microns. (The sample could also have been prepared by cutting a large rope band, e.g. 1,000,000 denier, with a Lummus cutter.) The fiber had tenacity of 4.5 grams per denier and elongation of 24.0%. It is important to cut the hollow fiber with sharp blades to keep fiber voids fully open (see Figure 2) .
  • the sample was placed in a petri dish and carefully pushed down with a small metal plate weighing approximately 20 grams to keep the sample down in the dish during vacuum operation (see Figure 3).
  • a 30.0% salt solution was poured into the dish until the fiber sample was completely submerged in the solution.
  • the vacuum pump (a Fisher Scientific Precision Direct-Drive Pump Model DD-90) was turned on for five minutes to obtain a vacuum of at least 1.0 x 10" 2 torr. Numerous air bubbles are observed escaping from the fiber sample at this time. (It is desirable that the air in the fiber voids be completely removed and a vacuum created.) Then the vacuum pump was turned off and the vacuum chamber was rapidly returned to atmospheric pressure.
  • the filled fibers were then washed thoroughly with distilled water to remove all salt solutions from the surface of fibers. Then the fibers were submerged in 200 ml. of distilled water. The amount of salt solute diffused into the distilled water from the filled fibers was measured by a Fisher Scientific conductivity meter (Cat. No. 09 325 360, Range 0-19,990 micromhos) , since the amount of sodium chloride ions in the distilled water is directly proportional to the conductivity of the current in the solution. The salt was diffused out of the fibers rapidly during the first day and thereafter the salt diffusion rate gradually slowed down. Upon completion of the test, the fibers still maintained their original tensile properties, i.e., tenacity of 4.5 grams per denier and elongation of 24.0%.
  • Table I also shows the results of the preparation of hollow commercially available DacronTM polyester fiber, 5.5 denier per filament T-374W (single-hole with 15% void) , with vacuum-filling of the hollow fibers with salt solution, and testing for the controlled time release of the salt solution.
  • a 4.0 gram sample of 3.81 centimeters cut length was prepared by cutting the fibers with a sharp razor.
  • the fiber diameter was 23.75 microns and the void diameter was 9.20 microns.
  • the fiber had tenacity of 3.8 grams per denier and elongation of 36.0%.
  • the fibers were vacuum- filled with salt solution as described above.
  • the diffusion rate of 5.5 denier per filament of fiber was more rapid than that for 1.3 denier per filament.
  • the vacuum-filling and diffusion test did not affect tensile properties of the fibers.
  • Table I also illustrates the results of the preparation of 4- hole hollow DacronTM polyester fiber, 5.5 denier per filament T- 808 (4-hole with 15% void) .
  • a 4.0 gram sample of 3.81 centimeters cut length was prepared by cutting the fibers with a sharp razor. The fiber had tenacity of 3.5 grams per denier and elongation of 37.0%. The sample was subsequently prepared and tested as described above. Its diffusion rate was slower than that for 5.5 denier per filament T-374W.
  • Table II demonstrates the results of filling knit fabric produced from DacronTM fiber, 1.3 denier per filament, 3.81 centimeters cut length, T-727W hollow fibers, with a saturated salt solution, and then testing for controlled time release of the salt solution.
  • a fiber sample with a tow denier of 1,000,000 denier was commercially cut on a tow carousel cutter manufactured by Lummus Industries (of Columbus, Georgia) to produce fibers with 3.81 centimeters cut length.
  • a tow carousel cutter manufactured by Lummus Industries (of Columbus, Georgia) to produce fibers with 3.81 centimeters cut length.
  • yarns with 10 to 1 and 20 to 1 cotton counts were produced. These yarns were then knit into a sample fabric on a commercial knitting machine for testing.
  • a 4.0 gram fabric sample was cut with a sharp razor and filled with 30.0% salt solution as described for Table I. After rinsing the fabric sample thoroughly with distilled water to remove salt solution from the surface of the fabric, the sample was submerged in 400 ml. of distilled water to test for the diffusion rate of salt from the fiber voids into the water. The diffusion rate behavior was identical to that of 1.3 denier per filament fiber, demonstrating that yarn making and fabric knitting processes did not deform the fibers or alter their drug delivery properties
  • Table II also shows filling of knit fabric produced from 5.5 denier per filament, 3.81 centimeters cut length T-374W hollow fibers, with 30% salt solution, and testing for the controlled time release of the salt solution.
  • a fiber sample with a rope denier of 1,000,000 denier was commercially cut on a Lummus cutter to produce fibers from 3.81 centimeters cut length.
  • yarns with 10 to 1 and 20 to 1 cotton counts were produced.
  • a 4.0 gram fabric sample was prepared and vacuum-tested as shown in Table II. The diffusion rate was very similar to these examples in Table I, indicating that yarn and fabric making processes did not affect the fiber voids.
  • Table III demonstrates the preparation of 1-hole hollow DacronTM polyester fiber, 1.3 denier per filament T-727W, and DacronTM fiber 5.5 denier per filament T-374W and its knit fabric, with vacuum-filling of the hollow fibers and knit fabric with Heparin (an anticoagulant) and testing for the controlled time release of Heparin.
  • Aristocort (a steroid) at a concentration of 320 mg/15 cc was filled into hollow fiber in a fashion similar to the Heparin described above.
  • the diffusion rate behavior was similar to that of Heparin.
  • Cefazolin an antibiotic
  • Cefazolin an antibiotic
  • the diffusion rate was very low from the beginning, unlike the above solutions.
  • Knit fabric samples produced from the hollow fibers essentially maintained the diffusion rates of the non-knit fiber samples, indicting that the fabric making process did not affect each fiber's void.
  • Cefazolin an antibiotic had a higher diffusion rate than Aristocort and a more sustained drug release than Heparin. This pattern is ideally suited for clinical applications since anti-biotics are better applied clinically when applied locally in high concentrations for a prolonged time. Heparin, however, is needed only for a short period of time to prevent early thrombosis, and steroids are used in small concentrations for a prolonged time.
  • the diffusion rate of the present invention is equal to the amount of the solute diffused out of the hollow fiber, divided by the total cross-section area of the hollow fiber voids. This is illustrated in the following formula:
  • Diffusion Rate Amount of solute diffused out of hollow fiber (total cross-section area of hollow fiber voids)
  • the diffusion rate is measured in units of grams per square centimeter.
  • the diffusion rate is proportional to the percentage of the fiber cross-section that is hollow divided by the length of the fiber. This is illustrated by the formula:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Textile Engineering (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Artificial Filaments (AREA)

Abstract

The present invention is a timed release drug delivery system using hollow fibers. The drug contents of the voids in the fibers are delivered to the immediate environment of the fiber through the two open ends of each fiber. The present invention further includes a method of using a vacuum chamber for filling the fibers with the drugs to be delivered, and a method to control the manufacturing process of the hollow fibers containing drugs to obtain a certain rate of drug release. The present invention further includes fabrics manufactured from such drug delivery fibers, and articles made from such fabrics, such as vascular grafts and disposable surgical clothing.

Description

the hollow space are delivered to the immediate environment of the fiber through the two ends of the fibers to which the interior hollow reaches.
The present invention also includes a method of using a vacuum chamber for filling the hollow fibers with the contents to be delivered. This comprises taking the original hollow fibers, with only air trapped in the hollow spaces within the fibers, and submerging the fibers in a container containing a solution of the drugs or other chemicals that are targeted to be contained in the fibers. The container with the solution of fibers is then placed in a vacuum chamber and the air pressure is reduced in the vacuum chamber. This draws out the air within the hollow within the fiber, creating a vacuum in the fiber voids. With the fibers still submerged in the solution, the air pressure is then restored inside the vacuum chamber. This causes the vacuum within the fibers to draw the liquid solution into the hollows of the fibers, replacing the vacuum with the liquid solution. The fibers can then be examined by microscopy. Fibers filled with liquid look clear without dark streaks because the refractive indexes of the fiber and the liquid are similar. However, unremoved air remaining in the hollows in the fibers appears as dark streaks because of significantly different refractive indexes of the fiber and the air.
A Brief Description of the Drawings.
Figure 1 shows a cross section of a typical single-hole hollow fiber.
Figure 2 shows a schematic side view of a typical single-hole hollow fiber.
Figure 3 shows a schematic view of the apparatus for filling the hollow fibers with a substance. Figure 4 shows a schematic side view of a hollow fiber submerged in a liquid but still full of air.
Figure 5 shows a hollow fiber submerged in a liquid when the atmospheric pressure is being reduced, drawing the air out of the hollow.
Figure 6 shows a schematic side view of a hollow fiber after the hollow fiber void is filled with liquid.
Figure 7 shows a cross section of a typical four-hole hollow fiber.
Figure 8 shows a cross section of a typical seven-hole fiber.
Detailed Description of the Preferred Embodiments
Figure 1 shows a cross section view of a typical single-hole hollow fiber with the fiber material 1 and the hollow space 2.
Figure 2 shows a side schematic view of a typical hollow fiber showing the fiber material 1, the hollow space 2 inside the fiber, and the end of the hollow which allows air and liquid to enter and exit through the end of the fiber 3.
Figure 3 shows a schematic view of the apparatus using a vacuum chamber to fill the substance into the fiber. A mass of fibers 4 is shown as hash marks. These are placed in a container 5 which holds a liquid substance 6. The container 5 with the fibers 4 and liquid substance 6 is placed within a vacuum chamber 7 which has an air exit 8 and vacuum pump 9. When the vacuum pump 9 is operated, air is withdrawn from inside the vacuum chamber 7 creating the vacuum inside the chamber as well as inside the hollow fiber. When the control valve is loosened, air is let back into the vacuum chamber 7 allowing the air pressure there to return to normal. To fill the substance into the hollow in the fiber, the fibers 4 are placed in the container 5 and the solution 6 is added submerging the fibers. Figure 4 shows a schematic cross sectional view of a fiber in this situation. The fiber is surrounded by a liquid solution which penetrates slightly through the ends of the fiber by capillary action.
Then most of the air in the chamber 7 is withdrawn, creating a partial vacuum in the chamber 7. This causes the air within the hollow to expand, creating a partial vacuum in the hollow fiber. The expanding air in the hollow leaves the fibers, bubbling through the liquid. Figure 5 shows this condition with air 12 leaving the fiber through each end 3.
Then the air is let back into the chamber increasing the air pressure back to normal. This causes the remaining air inside the hollow of the fiber to contract, drawing the liquid into the fiber. Figure 6 shows a cross sectional view of the fiber in this condition. Liquid 11 has been drawn into the fiber filling the entire hollow.
The rate of delivery of the contents from the fibers is controlled by controlling the length of the fibers. That is, the rate of delivery of the contents will be approximately inversely proportional to the length of the fiber. That is, longer fibers of a certain length X will have a rate of delivery that is one half of the rate of delivery of shorter fibers with a length of one half X. this is because the shorter fibers will have twice the number of end holes per unit weight of fiber or per unit weight of contents held and to be delivered.
The rate of delivery can also be varied by changing the total cross-sectional area of the hollows. The total percentage hollow area in cross section can be altered by changing each fiber's percentage of hollowness. A higher rate of delivery can be obtained by increasing each fiber's percentage hollowness. Likewise, a lower rate of delivery can be obtained by reducing the fiber's percentage hollowness.
The rate of delivery of the contents can also be controlled by controlling the fiber size. A larger fiber will deliver the drug at a higher rate, and a smaller fiber will deliver the drug at a lower rate.
Also, the rate of delivery of the contents can be controlled by controlling the concentration of the drug. A higher drug concentration yields a higher diffusion rate. A lower concentration yields a lower diffusion rate.
The rate of delivery of the contents from the fibers may also be controlled by using a dull instrument to cut the fibers. A dull instrument rather than a sharp instrument will partially pinch the fiber in cutting it, thereby restricting the size of the end hole in the fiber.
These approaches permit the fiber to have a rate of delivery adjusted to the intended use, which is easily obtained and precisely controlled without degrading the physical tguality of the material. It is relatively simple to precisely control and monitor the length to which the fibers are cut. Likewise cutting the fibers does not generally degrade the material of the fiber and therefore permits the filled fiber to be used in a woven, knitted, or felt-like matted fabric. This in turn facilitates the manufacture of articles such as vascular grafts and bandages from the impregnated material without using a mixture of other fibers for strength.
Examples of how the basic unfilled fibers may be manufactured and purchased are indicated in U.S. Patent 3,772,137, by Tolliver. Fibers similar to those described are currently being manufactured by the DuPont Company from polyethylene terephthalate (often known as "Dacron™" when manufactured by DuPont) , and by other companies from various substances. Fibers treated in this manner may be made into fabrics, and sheets or tubes. Various drugs in solution may be filled into the hollow fibers in this manner. Basically any liquid or dissolved drug or chemical can be so filled. Examples of drugs that may be used for medical purposes include antibodies, antibiotics, anticoagulants, cardiac medication, anti-viral medication, anti- AIDS medication, anti-metabolites, anti-fungal agents and steroids. Substances in slurries, suspensions, or emulsions can also be so filled into the fibers.
Tests run by the inventor have shown that this method deposits drug solutions within hollow fibers. In the tests, the fibers released the drugs slowly at rates that have been made to vary from 3 days to 2 weeks by altering the length of the fibers, the number of hollows in each fiber, and the fiber diameter.
Basic hollow fibers of this type can be made of polyethylene terephthalate, rayon, nylon, Teflon™ or cotton. Cotton is a natural fiber that is naturally hollow. Applications of such impregnated fibers and materials can be used for both medical and non-medica1 purposes.
Fibers and fabrics made in this manner, that are treated with antibiotics to prevent infection and to encourage healing, can be used for certain kinds of prostheses, such as vascular grafts. An artificial graft made of such material can be filled with an antibiotic to prevent post-operation infections around the surgical field, with steroids to prevent rejection of the graft material, and with antimetabolites to prevent excessive scar formation around the graft. Likewise they may be filled with Heparin, an anticoagulant, to prevent excessive clotting around the prosthesis.
Other applications include filling the fibers with an antiseptic and an antifungal agent and manufacturing the material into disposable hospital sheets. Also surgical gowns, caps and masks can be made out of material filled with antiseptic or antiviral agents (including antiviral agents effective against AIDS) . bandages can also be made out of materials treated with antiseptics to avoid infection or with growth stimulating agents to promote healing.
Furthermore insect repellants or insecticides can be filled into materials and fabrics in this manner to make clothing that repels insects.
The present invention may also be used to deliver antifungal agents through diapers to prevent diaper rash. Such a drug used in this manner would release from the fabric only when wet, which is of course when they are most needed in this application.
Where the active ingredient to be placed in the fibers is normally a dry powder, then the ingredient must be dissolved in water, alcohol, or another solvent (or placed in a liquid in an emulsion, suspension, slurry or other form) , in order to be put into the hollow fiber as discussed above.
Once the fiber is filled with the active ingredient, the fiber will usually be dried before being worked or used. This can be done by freeze-drying, convection drying, or by micro-wave or other heating. This will leave the dry active ingredient in the hollow of the dry fiber, which can then be worked to make the final product (which can be stored in dry form) .
Then just before use, the product made from the fiber can be wetted with the appropriate liquid to restore the active ingredient to its liquid form and make it readily diffusible out of the fiber. The product also can be used dry where it will be adequately wetted after application (due to the wetness of the site of use) to allow diffusion of the active ingredient. Active ingredients that are inherently liquids, of course, cannot be dried, and must be worked, stored and used as liquids.
The embodiments as illustrated and discussed in this specification are intended only to teach those skilled in the art the best way known to the inventor to make the invention. Nothing in the specification should be considered as limiting the scope of the present invention. Many changes could be made by those skilled in the art to produce equivalent inventions without departing from this invention. The present invention should be limited only by the following claims and their legal equivalents.
For example, any natural and artificial materials may be used to make the hollow fibers which are then filled with the agents for later delivery. Furthermore the filled fibers may be mixed and used with a variety of other fibers that are untreated or treated, to form composite materials for uses incorporating delivery of the drugs or other carried agents. Furthermore different medical and non-medical agents and chemicals not described herein may also be used for delivery by the hollow fibers described herein. Furthermore the material made from the fibers, and the fibers themselves, may be manufactured into a variety of other finished products which could then be used for other uses including the timed delivery of the agents that they contain.
Furthermore the hollow fibers can also be made of cellulose, polyacrylonitrile, acetate, rayon, polyamide (nylon) , polyethylene terephthalate (polyester), cotton, polyvinyl alcohol, polyvinyl, polyethylene, polypeptide, polypropylene, polystyrene, polyvinylchloride, or polyurethane.
In the experiments, a vacuum in the chamber was used of from 10-2 torr. to 10-4 torr. , but other vacuum pressures can be used. Any drug may be incorporated into the hollow by the present invention, and this may include hydrophilic (aqueous based) , hydrophobic (oil or lipid based) , or slurries (liquid in combination with solid particles) . The drugs or other contents may be released from the hollows within the fibers by diffusion, vaporization, capillary action, liquid flow, liquid leakage, or other means. Where the drug of other contents are eventually found in the hollow in solid form (either by incorporation in a slurry, the liquid portion of which later evaporates, leaving the solid drug particles behind, or by incorporation in a solution, where the liquid later evaporates, leaving the dissolved drugs to come out of the solution as a solid) , then the solid drugs may leave the hollow fiber by redissolving when in contact with new liquids and moving out by diffusion, capillary action, or a liquid flow.
Fabrics made out of the treated materials as described herein may be knitted, woven, or non-woven fabrics.
Medical sheets and gowns are currently often made by non- woven polyethylene terephthalate fibers which are chopped are then pressed. They may be bonded or mechanically-entangled or otherwise formed into fabric in a method similar to manufactured paper. Articles that may be made out of materials treated in this manner may include also disposable shoe covers for the surgical theater. Furthermore, a non-woven material may be used to make products such as diapers, sheets, masks, gowns, surgical caps, shoe covers and bandages.
Knitted or woven fabrics may be used for the manufacture of vascular grafts, other prosthetic grafts, sutures, pillows, disposable tarps, disposable clothes or nets, or other materials.
Fragrances or sleep-inducing drugs may also be incorporated in the materials to be released as vapors.
The present invention may also be incorporated into artificial insulating fabrics such as Thinsulate™, to make insulated disposable clothes or nets filled with chemicals. These chemicals can include insect repellant to be used in sporting or outdoor environments. Likewise, mildew resistant chemicals or drugs could be used for such outdoor applications. Furthermore, rain gear may be made of hollow fiber, fabrics treated in this matter to contain water-repellant materials. This may yield a fabric that is both water repellant but can "breathe", that is, it can pass air and water vapor between the weave of the fabric.
Note that hollow polyethylene terephthalate fibers are hydrophobic and normally do not wet well. However, these fibers can be made hydrophilic (i.e., easily wetable) by treating them with a basic solution. For example, hollow polyethylene terephthalate fibers can be treated with a basic solution such as sodium hydroxide and ethanol, and then rinsed with distilled water, to make them hydrophilic.
For example, for convenience in explanation, embodiments are shown and described in this specification with fibers with one axial hollow. However, a fiber with multiple parallel axial hollows within each length of fiber can equally as well embody this invention. For example, fibers are currently made and can be used in the present invention that have one, four and seven hollows, respectively, running for the length of the fiber.
Figure 7 shows a cross section view of a four-hole hollow fiber with the fiber material 1 and the four hollow spaces 2. Figure 8 shows a cross section view of a seven-hole hollow fiber with the fiber material 1 and the seven hollow spaces 2.
Experimental Results
The inventor undertook experiments using the present invention, and the results are indicated in Tables I, II and III.
Table I describes the results of preparation of commercially available hollow Dacron™ (polyethylene terephthalate made by DuPont) fiber, 1.3 denier per filament T-727W (single-hole with 15% void) , with vacuum-filling of the hollow fibers with salt solution, and testing the filled fiber for controlled time release of the salt solution. A 4.0 gram sample of 3.81 centimeters cut length was prepared by cutting the fiber with a sharp razor. The fiber diameter was 11.56 microns and the void diameter was 4.49 microns. (The sample could also have been prepared by cutting a large rope band, e.g. 1,000,000 denier, with a Lummus cutter.) The fiber had tenacity of 4.5 grams per denier and elongation of 24.0%. It is important to cut the hollow fiber with sharp blades to keep fiber voids fully open (see Figure 2) .
The sample was placed in a petri dish and carefully pushed down with a small metal plate weighing approximately 20 grams to keep the sample down in the dish during vacuum operation (see Figure 3). A 30.0% salt solution was poured into the dish until the fiber sample was completely submerged in the solution. After the sample dish was placed in a vacuum chamber, the vacuum pump (a Fisher Scientific Precision Direct-Drive Pump Model DD-90) was turned on for five minutes to obtain a vacuum of at least 1.0 x 10"2 torr. Numerous air bubbles are observed escaping from the fiber sample at this time. (It is desirable that the air in the fiber voids be completely removed and a vacuum created.) Then the vacuum pump was turned off and the vacuum chamber was rapidly returned to atmospheric pressure. This caused the vacuum in the fiber voids to be replaced with salt solution. All fibers were completely filled with salt solution in five minutes. These solution-filled fibers looked clear under an optical microscope while the air-filled fibers have dark streaks along the voids because of refractive index differences.
The filled fibers were then washed thoroughly with distilled water to remove all salt solutions from the surface of fibers. Then the fibers were submerged in 200 ml. of distilled water. The amount of salt solute diffused into the distilled water from the filled fibers was measured by a Fisher Scientific conductivity meter (Cat. No. 09 325 360, Range 0-19,990 micromhos) , since the amount of sodium chloride ions in the distilled water is directly proportional to the conductivity of the current in the solution. The salt was diffused out of the fibers rapidly during the first day and thereafter the salt diffusion rate gradually slowed down. Upon completion of the test, the fibers still maintained their original tensile properties, i.e., tenacity of 4.5 grams per denier and elongation of 24.0%.
Table I also shows the results of the preparation of hollow commercially available Dacron™ polyester fiber, 5.5 denier per filament T-374W (single-hole with 15% void) , with vacuum-filling of the hollow fibers with salt solution, and testing for the controlled time release of the salt solution. A 4.0 gram sample of 3.81 centimeters cut length was prepared by cutting the fibers with a sharp razor. The fiber diameter was 23.75 microns and the void diameter was 9.20 microns. The fiber had tenacity of 3.8 grams per denier and elongation of 36.0%. The fibers were vacuum- filled with salt solution as described above. The diffusion rate of 5.5 denier per filament of fiber was more rapid than that for 1.3 denier per filament. The vacuum-filling and diffusion test did not affect tensile properties of the fibers.
Table I also illustrates the results of the preparation of 4- hole hollow Dacron™ polyester fiber, 5.5 denier per filament T- 808 (4-hole with 15% void) . A 4.0 gram sample of 3.81 centimeters cut length was prepared by cutting the fibers with a sharp razor. The fiber had tenacity of 3.5 grams per denier and elongation of 37.0%. The sample was subsequently prepared and tested as described above. Its diffusion rate was slower than that for 5.5 denier per filament T-374W.
Table II demonstrates the results of filling knit fabric produced from Dacron™ fiber, 1.3 denier per filament, 3.81 centimeters cut length, T-727W hollow fibers, with a saturated salt solution, and then testing for controlled time release of the salt solution.
A fiber sample with a tow denier of 1,000,000 denier was commercially cut on a tow carousel cutter manufactured by Lummus Industries (of Columbus, Georgia) to produce fibers with 3.81 centimeters cut length. Using conventional cotton textile system processing equipment from carding, drawing, and roving to spinning, yarns with 10 to 1 and 20 to 1 cotton counts were produced. These yarns were then knit into a sample fabric on a commercial knitting machine for testing. A 4.0 gram fabric sample was cut with a sharp razor and filled with 30.0% salt solution as described for Table I. After rinsing the fabric sample thoroughly with distilled water to remove salt solution from the surface of the fabric, the sample was submerged in 400 ml. of distilled water to test for the diffusion rate of salt from the fiber voids into the water. The diffusion rate behavior was identical to that of 1.3 denier per filament fiber, demonstrating that yarn making and fabric knitting processes did not deform the fibers or alter their drug delivery properties.
Table II also shows filling of knit fabric produced from 5.5 denier per filament, 3.81 centimeters cut length T-374W hollow fibers, with 30% salt solution, and testing for the controlled time release of the salt solution. A fiber sample with a rope denier of 1,000,000 denier was commercially cut on a Lummus cutter to produce fibers from 3.81 centimeters cut length. Using conventional cotton textile system processing equipment from carding, drafting, and roving to spinning, yarns with 10 to 1 and 20 to 1 cotton counts were produced. A 4.0 gram fabric sample was prepared and vacuum-tested as shown in Table II. The diffusion rate was very similar to these examples in Table I, indicating that yarn and fabric making processes did not affect the fiber voids.
Application to Specific Drugs
Heparin
Table III demonstrates the preparation of 1-hole hollow Dacron™ polyester fiber, 1.3 denier per filament T-727W, and Dacron™ fiber 5.5 denier per filament T-374W and its knit fabric, with vacuum-filling of the hollow fibers and knit fabric with Heparin (an anticoagulant) and testing for the controlled time release of Heparin.
Using commercially available 1-hole hollow Dacron™ polyester fibers, 1.3 denier per filament T-727W, and 5.5 denier per filament T-374W and its knit fabric, a 4.0 gram sample for each item was prepared for testing as described above for Table I. Each sample was vacuum-filled with Heparin at a concentration of 40,000 units per 150 cc . The diffusion rate was rapid initially and was gradual later, similar to the samples with saturated salt solutions.
Aristocort
Aristocort (a steroid) at a concentration of 320 mg/15 cc was filled into hollow fiber in a fashion similar to the Heparin described above. The diffusion rate behavior was similar to that of Heparin.
Cefazolin
Cefazolin (an antibiotic) at a concentration of 4 mg/75 cc was filled into hollow fibers in a manner similar to the Heparin described above. The diffusion rate was very low from the beginning, unlike the above solutions.
From the information in Table 1, one can conclude that hollow fibers having different deniers and different numbers of holes can be easily filled with solutions of various substrates which later diffuse out of the hollow fibers in the presence of a solvent or distilled water. Sodium chloride effectively diffused out of 1.3 dpf (denier per filament) fine fibers as well as the larger 5.5 dpf fibers.
The following conclusions are drawn from the information in Table II. 1) Knit fabric samples produced from the hollow fibers essentially maintained the diffusion rates of the non-knit fiber samples, indicting that the fabric making process did not affect each fiber's void.
2) Coarse fabric samples produced from coarse yarns (10 to 1 cotton count) and softer fabric samples produced from finer yarns (20 to 1 cotton count) had about the same diffusion rate. Thus, fabric samples having different textures or aesthetics can be produced for different applications without affecting diffusion rates.
The following conclusions are drawn from the information in Table III.
1) All drugs filled easily into hollow fibers and effectively diffused out of hollow fibers or knit fabrics produced from hollow fibers.
2) Drugs diffused out of knit fabrics as effectively as from hollow fibers.
3) Cefazolin (an antibiotic) had a higher diffusion rate than Aristocort and a more sustained drug release than Heparin. This pattern is ideally suited for clinical applications since anti-biotics are better applied clinically when applied locally in high concentrations for a prolonged time. Heparin, however, is needed only for a short period of time to prevent early thrombosis, and steroids are used in small concentrations for a prolonged time.
Diffusion Rate
The diffusion rate of the present invention is equal to the amount of the solute diffused out of the hollow fiber, divided by the total cross-section area of the hollow fiber voids. This is illustrated in the following formula:
Diffusion Rate = Amount of solute diffused out of hollow fiber (total cross-section area of hollow fiber voids)
The diffusion rate is measured in units of grams per square centimeter.
The diffusion rate is proportional to the percentage of the fiber cross-section that is hollow divided by the length of the fiber. This is illustrated by the formula:
Diffusion Rate 3 Hollow cross-section % length of fiber

Claims

ClaimsI claim.
1. A manufacture comprising:
(a) a hollow fiber, containing a number of voids, with each void open to the exterior of the fiber at each end of the fiber, and
(b) a substance filling the voids.
2. The invention in Claim 1 where the fiber is made of one member of the group comprising of polyethylene terephthalate
(polyester) , rayon, cotton, cellulose, polyacrylonitrile, acetate, polyvinyl alcohol, polyvinyl, polyamide (nylon), polyethylene, polypeptide, polypropylene, polystyrene, polyvinylchloride, and polyurethane.
3. The invention in Claim 1, where the substance is one member of the group consisting of medical drugs, insect repellant, water repellant, and fragrances.
4. The invention in Claim 1 where the substance is one member of the group of liquids, slurries, and dry powders.
5. The invention in Claim 4, where the liquid is hydrophilic.
6. The invention in Claim 4, where the liquid is hydrophobic.
7. A textile fabric comprising:
(a) a plurality of hollow fibers, with each fiber containing a number of hollow voids, with each void open to the exterior of the fiber at each end of the fiber, and
(b) a substance filling the voids.
8. The invention in Claim 7, where the fabric is made by weaving the fibers.
9. The invention in Claim 7, where the fabric is made by knitting the fibers.
10. The invention in Claim 7, where the fabric is made by mechanically-entangling and pressing the fiber.
11. An article of clothing comprising:
(a) textile material made of hollow fibers, with each fiber containing a number of hollow voids, with each void open to the exterior of the fiber at each end of the fiber, and
(b) a substance filling the voids.
12. The invention in Claim 11, where the fibers are made of one member of the group consisting of polyethylene terephthalate
(polyester) , rayon, cotton, cellulose, polyacrylonitrile, acetate, polyvinyl alcohol, polyvinyl, polyamide (nylon), polyethylene, polypeptide, polypropylene, polystyrene, polyvinylchloride, and polyurethane.
13. The invention in Claim 11, where the substance is one member of the group consisting of medical drugs, insect repellant, water repellant, and fragrances.
14. The invention in Claim 11, where the article is one member of the group of diapers, sheets, masks, gowns, surgical caps, shoe covers, and rain coats.
15. A medical device comprising: (a) a textile material made of hollow fibers, with each fiber containing a number of hollow voids, with each void open to the exterior of the fiber at each end of the fiber, and
(b) a substance filling the voids.
16. The invention in Claim 15, where the fibers are made of one member of the group consisting of polyethylene terephthalate
(polyester) , rayon, cotton, cellulose, polyacrylonitrile, acetate, polyvinyl alcohol, polyvinyl, polyamide (nylon), polyethylene, polypeptide, polypropylene, polystyrene, polyvinylchloride, and polyurethane.
17. The invention in Claim 15, where the substance is one member of the group consisting of medical drugs, insect repellant, water repellant, and fragrances.
18. The invention in Claim 15, where the device is a prosthesis.
19. The invention in Claim 18, where the prosthesis is a vascular graft.
20. The method of putting a substance in the voids of a hollow fiber comprising:
(a) cutting the ends of the fiber to make a plurality of fibers of a desired average length,
(b) submerging the cut fibers in a liquid containing a substance,
(c) placing the submerged fibers in a vacuum chamber,
(d) drawing the air out of the voids by reducing the air pressure in the vacuum chamber, and (e) drawing the liquid containing the substance into the voids by allowing the air pressure in the vacuum chamber to return to the ambient pressure.
21. The invention in Claim 20, further comprising:
(a) drying the liquid from the fiber, leaving the substance dry in the voids of the fiber.
22. The invention in Claim 20, where the fibers are made of one member of the group consisting of polyethylene terephthalate
(polyester) , rayon, cotton, cellulose, polyacrylonitrile, acetate, polyvinyl alcohol, polyvinyl, polyamide (nylon), polyethylene, polypeptide, polypropylene, polystyrene, polyvinylchloride, polyurethane.
23. The invention in Claim 20, where the substance is one member of the group consisting of medical drugs, insect repellant, water repellant, and fragrances.
24. The invention in Claim 11, where the substance is one member of the group of liquids, slurries, and dry powders.
25. A method of delivery of a drug consisting of:
(a) cutting a plurality of hollow fibers with voids,
(b) putting the drug in the voids of the fibers,
(c) making a textile fabric of such fibers,
(d) manufacturing an article from such fabric, and
(e) placing such fabric at the desired site of delivery of such drug.
26. The invention in Claim 25, where such article is one member of the group consisting of prostheses, bandages, diapers, and disposable surgical clothing.
27. The invention in Claim 25, where the substance exits the voids by capillary action.
28. The invention in Claim 25, where the substance exits the voids by vaporization.
29. The invention in Claim 25, where the substance exits the voids by liquid flow.
30. The invention in Claim 25, where the substance exits the voids by diffusion.
31. The invention in Claim 25, further comprising:
(a) drying the fibers before making the fabric, and
(b) wetting the fabric just before placing the fabric at the desired site of delivery of such drug.
32. A method of controlling the process of manufacture of hollow fibers containing a substance, to obtain a certain rate of delivery of such a substance, comprising:
(a) controlling the length to which the fibers are cut, comprising one step selected from the group of steps comprising (i) cutting the fibers to a shorter length to obtain a higher rate, and (ii) cutting the fibers to a longer length to obtain a lower rate;
(b) controlling the percentage of cross-section of the fibers represented by voids, comprising one step selected from the group of steps comprising (i) selecting fibers with voids of larger cross-sectional area to obtain a higher rate, and (ii) selecting fibers with voids of smaller cross- sectional area to obtain a lower rate;
(c) controlling the fiber size, comprising one step selected from the group of steps comprising (i) selecting fibers with a larger size to obtain a higher rate, and (ii) selecting fibers with a smaller size to obtain a lower rate; and
(d) controlling the percentage of the cross-sectional area of the fibers represented by the voids, comprising selecting one step from the group of steps comprising (i) selecting fibers with such a percentage that is higher, to obtain a higher rate, and (ii) selecting fibers with such a percentage that is lower, to obtain a lower rate, and
(e) controlling the concentration of the contents, comprising selecting one step from the group of steps comprising (i) selecting a higher concentration to obtain a higher rate, and (ii) selecting a lower concentration to obtain a lower rate.
EP94909798A 1993-02-19 1994-02-18 Drug delivery system using hollow fibers. Withdrawn EP0684815A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/019,884 US5538735A (en) 1993-02-19 1993-02-19 Method of making a drug delivery system using hollow fibers
US19884 1993-02-19
PCT/US1994/002037 WO1994018956A1 (en) 1993-02-19 1994-02-18 Drug delivery system using hollow fibers

Publications (2)

Publication Number Publication Date
EP0684815A1 true EP0684815A1 (en) 1995-12-06
EP0684815A4 EP0684815A4 (en) 1997-04-23

Family

ID=21795561

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94909798A Withdrawn EP0684815A4 (en) 1993-02-19 1994-02-18 Drug delivery system using hollow fibers.

Country Status (4)

Country Link
US (1) US5538735A (en)
EP (1) EP0684815A4 (en)
AU (1) AU6250194A (en)
WO (1) WO1994018956A1 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6527849B2 (en) * 1990-06-19 2003-03-04 Carolyn M. Dry Self-repairing, reinforced matrix materials
US6267782B1 (en) * 1997-11-20 2001-07-31 St. Jude Medical, Inc. Medical article with adhered antimicrobial metal
US6626919B1 (en) 1997-12-29 2003-09-30 Lee L. Swanstrom Method and apparatus for attaching or locking an implant to an anatomic vessel or hollow organ wall
US6669707B1 (en) 1998-07-21 2003-12-30 Lee L. Swanstrom Method and apparatus for attaching or locking an implant to an anatomic vessel or hollow organ wall
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
DK1339438T3 (en) 2000-11-29 2006-02-13 Allergan Inc Prevention of transplant rejection in the eye
RU2322233C2 (en) 2002-03-11 2008-04-20 Алькон, Инк. Implaned system for delivering medicinal preparations
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
CN1511979A (en) * 2002-12-27 2004-07-14 Technology for preparing core-shell structure function fiber
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
JP5014798B2 (en) * 2003-12-04 2012-08-29 エシコン・インコーポレイテッド Active sutures for therapeutic fluid delivery
US8257393B2 (en) * 2003-12-04 2012-09-04 Ethicon, Inc. Active suture for the delivery of therapeutic fluids
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
EP1600534A1 (en) * 2004-05-27 2005-11-30 Shenzhen Yang Qian Material Application Technology Co., Ltd. Process of manufacturing core-sheath composite fiber
DE102004032375A1 (en) * 2004-06-30 2006-01-26 Klaus Dr. Rennebeck Fiber, in particular hollow fiber and its use
US7811666B2 (en) * 2005-07-01 2010-10-12 Carolyn Dry Multiple function, self-repairing composites with special adhesives
US20070142804A1 (en) * 2005-12-16 2007-06-21 Bernard Bobby L Hollow-core fibers
US8267905B2 (en) 2006-05-01 2012-09-18 Neurosystec Corporation Apparatus and method for delivery of therapeutic and other types of agents
US7803148B2 (en) * 2006-06-09 2010-09-28 Neurosystec Corporation Flow-induced delivery from a drug mass
GB2475644B (en) * 2006-06-16 2011-11-16 Family Health Internat Vaginal drug delivery system and method
US7824383B2 (en) * 2006-06-16 2010-11-02 Family Health International Vaginal drug delivery system and method
US8137327B2 (en) * 2006-06-16 2012-03-20 Family Health International Vaginal drug delivery system and method
US20080065002A1 (en) * 2006-09-07 2008-03-13 Neurosystec Corporation Catheter for Localized Drug Delivery and/or Electrical Stimulation
EP1970001B1 (en) * 2007-03-16 2014-07-23 Brainlab AG Catheter with pressure sensoring
US20090259251A1 (en) * 2008-04-11 2009-10-15 Cohen Matthew D Loop suture
US20100291182A1 (en) * 2009-01-21 2010-11-18 Arsenal Medical, Inc. Drug-Loaded Fibers
US9283305B2 (en) 2009-07-09 2016-03-15 Medtronic Vascular, Inc. Hollow tubular drug eluting medical devices
US20110202016A1 (en) * 2009-08-24 2011-08-18 Arsenal Medical, Inc. Systems and methods relating to polymer foams
US10420862B2 (en) 2009-08-24 2019-09-24 Aresenal AAA, LLC. In-situ forming foams for treatment of aneurysms
US9044580B2 (en) 2009-08-24 2015-06-02 Arsenal Medical, Inc. In-situ forming foams with outer layer
US9173817B2 (en) 2009-08-24 2015-11-03 Arsenal Medical, Inc. In situ forming hemostatic foam implants
US8460745B2 (en) * 2009-09-20 2013-06-11 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
US20110070358A1 (en) 2009-09-20 2011-03-24 Medtronic Vascular, Inc. Method of forming hollow tubular drug eluting medical devices
US8828474B2 (en) 2009-09-20 2014-09-09 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
US8678046B2 (en) 2009-09-20 2014-03-25 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
EP2483460B1 (en) 2009-09-28 2015-09-02 Trustees Of Tufts College Method to prepare drawn silk egel fibers
US8968362B2 (en) 2010-04-08 2015-03-03 Covidien Lp Coated looped suture
ES2560218T3 (en) * 2010-07-02 2016-02-17 The Procter & Gamble Company Process for making films from bands of nonwoven material
CN103025930B (en) 2010-07-02 2014-11-12 宝洁公司 Method for delivering an active agent
RU2012154298A (en) 2010-07-02 2014-08-10 Дзе Проктер Энд Гэмбл Компани FILAMENTS CONTAINING SUITABLE FOR RECEPTION INSIDE ACTIVE AGENTS, NONWOVEN CLOTHES AND METHODS FOR THEIR MANUFACTURE
CA2803636C (en) 2010-07-02 2017-05-16 The Procter & Gamble Company Detergent product and method for making same
WO2012003319A2 (en) 2010-07-02 2012-01-05 The Procter & Gamble Company Filaments comprising an active agent nonwoven webs and methods for making same
US8333801B2 (en) 2010-09-17 2012-12-18 Medtronic Vascular, Inc. Method of Forming a Drug-Eluting Medical Device
US8632846B2 (en) * 2010-09-17 2014-01-21 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
US8616040B2 (en) 2010-09-17 2013-12-31 Medtronic Vascular, Inc. Method of forming a drug-eluting medical device
US9194058B2 (en) 2011-01-31 2015-11-24 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
US9034240B2 (en) 2011-01-31 2015-05-19 Arsenal Medical, Inc. Electrospinning process for fiber manufacture
US8968626B2 (en) 2011-01-31 2015-03-03 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
WO2012145652A1 (en) 2011-04-20 2012-10-26 Trustees Of Tufts College Dynamic silk coatings for implantable devices
CN102433763B (en) * 2011-08-26 2013-10-16 中国纺织科学研究院 Functional fiber, manufacturing method and fabric formed via weaving functional fiber
US8993831B2 (en) 2011-11-01 2015-03-31 Arsenal Medical, Inc. Foam and delivery system for treatment of postpartum hemorrhage
EP2827884A4 (en) * 2012-03-20 2015-09-16 Tufts College Silk reservoirs for drug delivery
EP2967938B1 (en) 2013-03-14 2017-03-01 Medtronic Vascular Inc. Method for manufacturing a stent and stent manufactured thereby
WO2017015571A1 (en) 2015-07-23 2017-01-26 Novaflux, Inc. Implants and constructs including hollow fibers
JP6622158B2 (en) * 2016-08-30 2019-12-18 富士フイルム株式会社 Blood dispensing adapter
EP3573722B1 (en) 2017-01-27 2022-02-23 The Procter & Gamble Company Compositions in the form of dissolvable solid structures comprising effervescent agglomerated particles
MX2019013048A (en) 2017-05-16 2019-12-11 Procter & Gamble Conditioning hair care compositions in the form of dissolvable solid structures.
KR20200086739A (en) 2018-01-26 2020-07-17 더 프록터 앤드 갬블 캄파니 Water soluble unit dose article containing enzyme
EP3743503A1 (en) 2018-01-26 2020-12-02 The Procter & Gamble Company Water-soluble articles and related processes
CA3087583C (en) 2018-01-26 2024-01-09 The Procter & Gamble Company Water-soluble unit dose articles comprising perfume
US11053466B2 (en) 2018-01-26 2021-07-06 The Procter & Gamble Company Water-soluble unit dose articles comprising perfume
WO2019168829A1 (en) 2018-02-27 2019-09-06 The Procter & Gamble Company A consumer product comprising a flat package containing unit dose articles
US10982176B2 (en) 2018-07-27 2021-04-20 The Procter & Gamble Company Process of laundering fabrics using a water-soluble unit dose article
US11666514B2 (en) 2018-09-21 2023-06-06 The Procter & Gamble Company Fibrous structures containing polymer matrix particles with perfume ingredients
US11859338B2 (en) 2019-01-28 2024-01-02 The Procter & Gamble Company Recyclable, renewable, or biodegradable package
EP3712237A1 (en) 2019-03-19 2020-09-23 The Procter & Gamble Company Fibrous water-soluble unit dose articles comprising water-soluble fibrous structures
WO2020191166A1 (en) 2019-03-19 2020-09-24 The Procter & Gamble Company Process of reducing malodors on fabrics
BR112021023244A2 (en) 2019-06-28 2022-01-04 Procter & Gamble Soluble solid fibrous articles containing anionic surfactants
CN115867357A (en) 2020-07-31 2023-03-28 宝洁公司 Water-soluble fiber pouch containing spherulites for hair care

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3926188A (en) * 1974-11-14 1975-12-16 Alza Corp Laminated drug dispenser
EP0227836A1 (en) * 1985-06-24 1987-07-08 Teijin Limited Sustained releasing patch
EP0253554A2 (en) * 1986-07-15 1988-01-20 Pfizer Inc. Controlled release drug-containing fibers
WO1992005776A1 (en) * 1990-10-01 1992-04-16 The Upjohn Company Lateral edge coated controlled release pharmaceutical compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3772137A (en) * 1968-09-30 1973-11-13 Du Pont Polyester pillow batt
US3745061A (en) * 1969-02-26 1973-07-10 Du Pont Synthetic filaments having at least three continuous nonround voids
JPS5136810B2 (en) * 1972-08-04 1976-10-12
JPS62169723A (en) * 1986-01-22 1987-07-25 Teisan Seiyaku Kk Sustained release preparation
US4833172A (en) * 1987-04-24 1989-05-23 Ppg Industries, Inc. Stretched microporous material
US4836763A (en) * 1988-07-29 1989-06-06 E. I. Dupont De Nemours And Company Seven hole spinneret
US5024671A (en) * 1988-09-19 1991-06-18 Baxter International Inc. Microporous vascular graft

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3926188A (en) * 1974-11-14 1975-12-16 Alza Corp Laminated drug dispenser
EP0227836A1 (en) * 1985-06-24 1987-07-08 Teijin Limited Sustained releasing patch
EP0253554A2 (en) * 1986-07-15 1988-01-20 Pfizer Inc. Controlled release drug-containing fibers
WO1992005776A1 (en) * 1990-10-01 1992-04-16 The Upjohn Company Lateral edge coated controlled release pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9418956A1 *

Also Published As

Publication number Publication date
EP0684815A4 (en) 1997-04-23
US5538735A (en) 1996-07-23
AU6250194A (en) 1994-09-14
WO1994018956A1 (en) 1994-09-01

Similar Documents

Publication Publication Date Title
US5538735A (en) Method of making a drug delivery system using hollow fibers
EP1490538B1 (en) Non-woven fiber assemblies
US3108357A (en) Compound absorbable prosthetic implants, fabrics and yarns therefor
NL193263C (en) A method of manufacturing a blood-tight artery that delivers a drug.
EP1353606B1 (en) Improved vascular prosthesis and method for production thereof
DE69426740T2 (en) Antibacterial vascular prosthesis and surgical sutures
EP2126166B1 (en) Fiber matting
US10920346B2 (en) Mechanically strong absorbent non-woven fibrous mats
US20030100944A1 (en) Vascular graft having a chemicaly bonded electrospun fibrous layer and method for making same
NO20180185A1 (en) Mechanical strong non-woven fibrous absorbent mats
EP1796750A1 (en) Antimicrobial implant with a flexible porous structure
CN100364621C (en) Artificial blood vessel silk fibroin pre-coagulation coating
DE69431228T2 (en) Infection-resistant surgical items and methods of making them
CN1425826A (en) Fibre product with slow-releasing function and its preparing method
EP0010865A1 (en) Product adapted for transcutaneous use
KR102233499B1 (en) 3-Dimensional fibrous scaffold
WO2023223946A1 (en) Fiber sheet structure including multiple wound yarn bundle formed of gelatin fiber bundle and thermoplastic resin fiber bundle
CZ300142B6 (en) Process for preparing fibrous biologically degradable materials serving as controlled release-medicament carriers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950919

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970307

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 20000728

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021219